PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Blood0 citationsOpen Access

Breaking new ground with antibody-drug conjugates in myeloma

View Full Paper
SUSaad Z. Usmani

Key Points

  • This research explores the role of antibody-drug conjugates in treating myeloma amidst regulatory challenges.
  • Analysis of market trends in antibody-drug conjugates and CAR T-cell therapies.
  • Evaluation of China's impact on global drug launch strategies.
  • Surveying patient demand and regulatory frameworks across various income settings.
  • The myeloma treatment market is experiencing substantial financial growth.
  • China's evolving CAR T-cell industry poses unique challenges for global strategies.
  • Regulatory processes significantly influence the timing and approach of drug launches.

Abstract

capital inflows, and strong patient demand. 4 The market is too large to ignore; however, its growing domestic CAR T-cell industry and opaque regulatory processes make global launch sequencing far less predictable for multinational firms.These features mean China can shape commercial strategies in ways that differ from both high-income and other middle-income settings.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Saad Z. Usmani (2026) studied this question.

synapsesocial.com/papers/69d1fc28a79560c99a0a1ce3https://doi.org/10.1182/blood.2025032443
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma2025 · 6 citations
  2. 2Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma2024 · 270 citations
  3. 3Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma2024 · 189 citations
  4. 4The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development2024 · 221 citations
  5. 5Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial2025 · 130 citations